Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma
Open Access
- 2 July 2026
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Abstract
Long-term follow-up of the CASSIOPEIA trial (NCT02541383) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and during maintenance therapy, in transplant-eligible patients newly diagnosed with multiple myeloma (MM). However, outcomes among CASSIOPEIA patients remain heterogeneous across treatment groups. Measurable residual disease (MRD) is a strong indicator of the depth and duration of therapeutic response and is independently associated with both PFS and overall survival (OS), but it does not fully capture the biological diversity of MM. We performed a risk prediction analysis based on transcriptomic subgroups in CASSIOPEIA patients. A subset of 628 patients was characterized using RNA sequencing and consensus clustering identified five subtypes of MM grouped into three transcriptomic risk categories, with estimated 72-month PFS rates of 70%, 51%, and 27% for low, intermediate, and high-risk groups, respectively, among patients who received daratumumab in at least one treatment phase. We showed that post-consolidation MRD negativity was higher in low- and high-risk groups compared to intermediate, and that its prognostic impact was distinct and reduced in high-risk patients. These findings indicate that transcriptomic profiling refines the prognostic value of MRD by identifying high-risk patients in whom MRD alone is insufficient to predict clinical outcome. This suggests that MRD negativity may not capture clinically relevant residual disease in this subgroup, potentially reflecting aggressive disease dynamics. Overall, these results support integrating baseline molecular features with MRD assessment and highlight the need for novel therapeutic strategies in high-risk MM.Keywords
Funding Information
- Institut National Du Cancer (INCa-DGOS-INSERM-ITMO Cancer_18011)
- Région pays de la Loire;, grant number: RPH2114NNA
This publication has 30 references indexed in Scilit:
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialThe Lancet Oncology, 2024
- International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaThe Lancet Oncology, 2024
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialThe Lancet Oncology, 2021
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialThe Lancet, 2020
- NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domainsNature Communications, 2019
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell linesLeukemia, 2017
- Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal nicheNature Communications, 2015
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaNature Communications, 2015